Sai Parenteral’s IPO Review: What Makes This Pharma IPO Different

Sai Parenteral’s IPO is open from March 24 to March 27, 2026, at a price band of ₹372 to ₹392 per share, with a minimum investment of ₹14,896 for 38 shares. The total issue size is ₹408.79 crore, including a fresh issue of ₹285 crore and an OFS of about ₹123.79 crore.

At the time of writing, the grey market premium, or GMP, is ₹0, which means the grey market is not showing any listing gain right now; this is only an informal signal, not a reliable predictor. Sai Parenteral is a pharma formulations and CDMO company that makes medicines like injectables, tablets, capsules, syrups, and ointments for India and export markets.

This IPO matters because the company is trying to move from a mostly domestic formulations business to a more global, regulated-market CDMO story. That sounds exciting, but it also means investors need to judge whether future growth can justify today’s valuation.

IPO Overview

• IPO Date: 24 to 27 Mar, 2026
• Total Issue Size: ₹408.79 crore
• Price Band: ₹372 to ₹392 per share
• Minimum Investment: ₹14,896
• Lot Size: 38 Shares
• Tentative Allotment Date: Mar 30, 2026
• Listing Date: Apr 2, 2026 (Tentative)
• GMP: The GMP for the Sai Parenteral's IPO is ₹0, reflecting a 0% gain over the issue price, according to Chittorgarh.com.

Disclaimer: GMP is an unofficial indicator and is subject to market volatility.

How Sai Parenteral's Makes Money

• Sai Parenteral makes money in two main ways: selling its own branded generic medicines and manufacturing medicines for other pharma companies under the CDMO model. In simple words, one part is its own product business, and the other part is like a behind-the-scenes manufacturing service.
• Its branded generic business sells medicines to government agencies, hospitals, stockists, and pharma buyers. The company is present in therapies like heart disease, diabetes, and infections, and it had 302 marketed products and 55 internally developed dossiers, which are approval-ready product files, as of the offer material.
• Its CDMO business is a faster-growing part. CDMO revenue rose from ₹5.31 crore in FY23 to ₹31.24 crore in FY25, and this matters because contract manufacturing can create repeat business if clients stay with the company for long production runs.
• ​The business is also fairly integrated. It sources raw materials, does in-house R&D, manufactures products in its own plants, and then supplies them through its distribution network, which gives it more control over quality and timelines than a pure outsourcing model.

Objectives of the IPO

• Plant expansion and upgrades: ₹110.79 crore will be used to expand and modernize Units I, II, III, and IV in Telangana, mainly to meet stricter global quality standards.
• New R&D centre: ₹18.02 crore will go toward setting up a new research centre at Bollaram to develop products and support future approvals.
• Debt repayment: ₹14.30 crore will be used to repay a Tata Capital term loan, which should reduce interest costs.
• Working capital: ₹33 crore is earmarked for day-to-day needs like raw materials, inventory, and customer credit.
• Noumed-related loan repayment: ₹35.64 crore will be used to repay the Kotak Mahindra Bank loan taken for the Noumed Pharmaceuticals acquisition.
• General corporate purposes: The remaining amount, capped at 25% of fresh issue proceeds, will be used for general business needs.

Strengths:

• The company is growing quickly, especially in contract manufacturing. Revenue from operations rose from ₹96.79 crore in FY23 to ₹163.10 crore in FY25, while CDMO revenue grew from ₹5.31 crore to ₹31.24 crore, which shows that the higher-growth side of the business is gaining traction.
• Sai is building a stronger global base through the Noumed deal. The acquisition gives it access to more than 451 approved dossiers and exclusive long-term supply agreements covering 526 products with Australian pharmacy chains, which can make export revenue more predictable.
• Even though the business is small, its operating quality looks good on some metrics. EBITDA margin was 24.18% in FY25, and ROCE, which shows how efficiently capital is used, stood at 28.92%, better than several larger peers.

Risks:

• The biggest concern is cash flow. The company reported a negative operating cash flow of ₹29.76 crore in FY24 and ₹66.01 crore in the first half of FY26, mainly because money gets stuck in inventory and receivables for a long time.
• Customer concentration is high. In FY25, the top 10 customers accounted for 69.47% of branded generic formulation revenue, which means losing even a few buyers could hurt sales in a meaningful way.
• Growth will not come smoothly. The company has said Units I and II may need to shut for around six months for upgrades, and management estimates the revenue impact could be about ₹42.20 crore, which is a real short-term hit for a business of this size.

For detailed information, visit Sai Parenteral's official IPO page at INDmoney.

Peer Comparison

Source: RHP, internal calculation

• Revenue scale: At ₹163.11 crore in FY25, Sai is the smallest company in its peer group by revenue. Senores was at ₹398.25 crore, while Gland Pharma was at ₹5,616.50 crore, so Sai is still much smaller than listed peers.
• Profitability: Sai’s EBITDA margin of 24.18% is strong for its size. It is well above Innova Captab’s 15.94% and close to the 24% to 27% range seen in some better-margin peers, which tells us the business is not weak operationally.
• Valuation: The issue looks expensive relative to many peers. Depending on the H1 FY26 annualized profit, the IPO is at 111.53x P/E ratio, while peers like Gland Pharma and Innova Captab trade much lower.
• Capital efficiency: This is where Sai stands out. Its ROCE of 28.92% is much better than many peers, and its fixed asset turnover ratio of 3.76x suggests it generates more revenue per rupee of plant investment than others in the comparison set.

IPO Valuation

At the upper price band of ₹392, Sai Parenteral’s post-issue market capitalization is about ₹1,732 crore.

On valuation, the stock does not look cheap on present earnings. Based on annualized H1 FY26 numbers, it is around 111.53x P/E, while larger peers like Gland Pharma and Innova Captab trade at meaningfully lower multiples.

A P/E ratio tells you how much investors are paying for each rupee of profit. So if the company is trading at 111.53x earnings, the market is paying ₹111.53 for every ₹1 of annual profit, which is a high price unless profits grow strongly over the next few years.

The market seems to be paying for the future, not the present. The premium rests on three things: CDMO growth, entry into regulated markets like Europe and Australia, and the Noumed acquisition creating a faster export path than building everything from scratch.

Who’s Making Money from the IPO?

An OFS, or Offer for Sale, simply means existing shareholders are selling their shares to the public, and that money goes to them, not to the company. In Sai Parenteral’s IPO, the OFS is entirely from non-promoter investors, not from the founding promoters.

The largest seller by value is Vikasa India EIF I Fund, which is cashing out about ₹16.86 crore and making roughly 5.6 times its investment. The highest return multiple belongs to Bhanwar Lal Chandak, who is exiting at about 11.2 times his original investment.

Several other investor shareholders are also selling at strong gains, including Tilokchand Punamchand Ostwal, Devendra Chawla, Ashish Maheshwari, Sreelekha Ganta, and others. The broader message is simple: early investors are booking profits, but the promoters themselves are not reducing control.

Analyst View

Sai Parenteral has a credible growth story. It has a diversified formulations base, a fast-growing CDMO business, a wider product mix, and the Noumed acquisition gives it a useful shortcut into regulated export markets instead of building everything slowly on its own.

The more interesting part is not today’s size but the shape of the business three years from now. If the unit upgrades finish on time, the Australia facility ramps up, and dossier-led exports scale, the company can look very different from the one investors see in recent numbers.

​Still, the valuation is not forgiving. Negative cash flow, slow receivables, customer concentration, and the planned plant shutdown mean this is a story where execution matters a lot more than headline excitement. For a patient investor, it may be a business worth tracking closely, but the current pricing leaves limited room for mistakes.

For a seamless application process, visit the INDmoney IPO page.

Disclaimer

Source: Sai Parenteral's RHP. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Please be informed that merely opening a trading and demat account will not guarantee investment in securities in the IPO. Investors are requested to do their own independent research and due diligence before investing in an IPO. Please read the SEBI-prescribed Combined Risk Disclosure Document prior to investing. This post is for general information and awareness purposes only and is nowhere to be considered as advice, recommendation, or solicitation of an offer to buy or sell, or subscribe for securities. INDstocks is acting as a distributor for non-broking products/services such as IPO, Mutual Fund, and Mutual Fund SIP. These are not exchange-traded products. All disputes with respect to the distribution activity would not have access to the Exchange investor redressal forum or the Arbitration mechanism. INDstocks Private Limited (formerly known as INDmoney Private Limited) does not provide any portfolio management services, nor is it an investment adviser. Logos above are the property of respective trademark owners, and by displaying them, INDstocks has no right, title, or interest in them. SEBI Stock Broking Registration No: INZ000305337, Trading and Clearing Member of NSE (90267, M70042) and BSE, BSE StarMF (6779), SEBI Depository Participant Reg. No. IN-DP-690-2022, Depository Participant ID: CDSL 12095500, Research Analyst Registration No. INH000018948 BSE RA Enlistment No. 6428.